PATENT CLAIM ANALYSIS

Application Number: 16094000
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["546", "084000"]

Abstract:
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonize or partially agonize) NLRP3 and TLR7 and/or TLR8 that are useful, e.g., for treating a condition, disease or disorder in which a decrease in NLRP3 and TLR7 and/or TLR8 activities (e.g., a condition, disease or disorder associated with repressed or impaired NLRP3 and TLR7 and/or TLR8 signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

Claim (Index 186):
The method of  claim 185 , wherein the one or more additional cancer therapies comprises surgery, radiotherapy, chemotherapy, toxin therapy, immunotherapy, cryotherapy or gene therapy, or a combination thereof.

Metadata:
- Claim Count in Document: 31.0
- Percentile: 97.0
- Lexical Diversity: 2.14062
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15898258', '14386747', '12310303', '16093990', '14336852']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.761785819953259
- 35 USC 102 Novelty (BERT): 0.5272009180528392
- Combined Prediction Score: 0.738327329763217
- Mean Citation Score: 270.686064
- Max Citation Score: 347.0156
- Similarity Product: 246.6999084301472

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test